ARTICLE | Clinical News
Dextofisopam: Phase IIb data
September 21, 2009 7:00 AM UTC
Data from a double-blind, U.S. Phase IIb trial in 324 patients showed that all 3 doses of twice-daily dextofisopam for 12 weeks missed the primary endpoint of percentage of weeks of adequate overall r...